Changes in oxidative stress in children undergoing chemotherapy for acute lymphoblastic leukemia (ALL) have not been well documented. To determine whether the measurement of the DNA oxidized base 8-oxodeoxyguanosine (8oxo-dG) may be a useful biomarker in this population, the authors conducted an observational study on 103 children with ALL. Blood samples were collected at diagnosis, during interim maintenance (IM), and during delayed intensification (DI). Blood mononuclear cell 8-oxo-dG, measured with an immunohistochemical method, decreased from diagnosis to IM (P = .01) and increased between IM and DI (P < .01). In a pilot study, bone marrow was also collected from 16 patients at diagnosis and after 28 days of treatment, but 8-oxo-dG remained the same. The relationship between plasma and dietary intake of antioxidants and the level of 8-oxo-dG was also explored. There was a direct relationship between the intake of vitamin E at diagnosis and bone marrow 8-oxo-dG (P = .03) and an inverse relationship between β-carotene intake and blood 8-oxo-dG at IM (P = .03) and vitamin A intake and blood 8-oxo-dG at DI (P = .003). Plasma vitamin C (P = .02) and total carotenoids (P = .01) were inversely related to blood 8-oxo-dG at IM. In contrast, higher plasma E/ total lipid levels were associated with higher 8-oxo-dG at IM and DI (P < .01). At IM, patients with higher 8-oxo-dG had an increased risk of chemotherapy dose reduction (P = .04). In conclusion, the level of 8-oxo-dG in blood mononuclear cells decreases after the start of chemotherapy and increases during aggressive chemotherapy in children with ALL.
Markers of oxidative stress may be useful for evaluating tumor burden and response to therapy in patients with cancer. A candidate marker, 8-oxodeoxyguanosine (8-oxo-dG) , is the most abundant and potentially mutagenic lesion induced in DNA by reactive oxygen species. 1 Both exogenous and endogenous sources of free radicals can contribute to its development such that the total level reflects the balance between its formation and repair.
A number of methods are available for quantitation of 8-oxo-dG in biological samples. 2 Several studies have demonstrated elevated levels of 8-oxo-dG as measured by gas chromatography/mass spectrometry (GC/MS) in tumor compared to normal tissue for brain, 1 lung, 1 stomach, 1 colon, 1 ovary, 1 and breast cancers 3, 4 and by high-performance liquid chromatography (HPLC) with electrochemical detection for colon, 1 kidney, 5 and breast cancers. 3, 4 Other studies have followed 8-oxo-dG levels in lymphocytes of patients with cancer and in healthy controls. In a European study that compared 8-oxo-dG levels by country and gender, levels of lymphocyte 8-oxo-dG, as measured by HPLC, in the blood of healthy men correlated positively with colorectal carcinoma rates from that country by the World Health Organization Database on Health Indicators, although in women there was a negative correlation between 8oxo-dG and stomach cancer. 6 In other studies, patients with lung cancer had higher levels of lymphocyte 8oxo-dG as compared to healthy controls by 32 Ppostlabeling, 7 and patients with gynecologic cancer had higher urinary 8-oxo-dG levels as compared to patients without carcinoma as measured by HPLC. 8 Levels of 8-oxo-dG can also be readily quantified by immunohistochemical techniques. This method has been used to identify levels of 8-oxo-dG in nasal biopsies of children in Mexico exposed to high levels of air pollutants 9 as well as in oral mucosal cells in smokers versus nonsmokers. 10 This technique was also used to evaluate the effect of a 6-month antioxidant supplement intervention in heavy smokers on levels of 8-oxo-dG in oral mucosal and mononuclear cells. 11 Studies are beginning to investigate whether cancer therapies whose mechanism of action involves free radical production are associated with increased levels of 8-oxo-dG. Two studies have measured 8-oxo-dG changes during radiation treatment by HPLC. A 2-fold increase in lymphocyte 8-oxo-dG levels after radiation treatment was observed in 4 patients with lung cancer. 12 A trend toward higher levels of lymphocyte 8oxo-dG after 1 week of radiation treatment was seen in patients with a variety of solid tumors, although the difference from baseline was not statistically significant. 13 The effects of doxorubicin on DNA oxidized bases in the peripheral blood mononuclear cells were investigated in a recent small cohort of women by GC/MS. No change was found in the level of 8-oxo-dG during the infusion or 72 to 96 hours later. 14 There were, however, more oxidized DNA bases of other types, FapyGua (1.6-fold increase), ThyGly (4.2-fold increase), 5-OH-Hyd (2.5-fold increase), FapyAde (2.4-fold increase), and 5-OH-MeUra (2.4-fold increase).
Urinary 8-oxo-dG levels, as measured by HPLC, have also been used as a marker of oxidative stress. Faure et al measured levels in 20 patients with cancer following a single bolus dose of doxorubicin. 15 Although the levels of 8-oxo-dG did not change, the level of another marker of DNA damage, 5hydroxymethyluracil, increased significantly in the urine. In another study, urinary excretion of 8-oxo-dG was shown to be higher in 136 patients with cancer than in 27 healthy controls in a mixed group of patients with cancer, primarily breast, lymphoma, teratoma, and head and neck cancer. 16 Similar results were observed in a study of patients with small-cell lung cancer. With initiation of therapy, decreases in 8oxo-dG levels were observed in patients with a partial or complete response to chemotherapy, whereas levels increased in those patients with stable disease or disease progression. 17 Although dietary antioxidant status may affect the formation of 8-oxo-dG, relatively few studies have looked at the effect of the diet on the level of 8-oxo-dG. In a study of adult men ingesting 300 g of brussels sprouts daily for 3 weeks, the level of 8-oxo-dG, as measured by HPLC, decreased in the urine by 28% when compared to controls given a cruciferous-free diet. 18 Studies of the effects of antioxidant supplementation on 8-oxo-dG levels have reported variable results. Vitamin C intake has been associated with a reduction in the level of 8-oxo-dG formation in sperm 19 as measured by HPLC. In contrast, supplementation with βcarotene 20 or vitamin C, vitamin E, or coenzyme Q10 21 in male smokers did not affect urinary 8-oxo-dG excretion as measured by HPLC. Similarly, in a study of heavy smokers supplemented with vitamin C, vitamin E, and β-carotene or placebo for 6 months, no difference in blood or oral cell 8-oxo-dG levels were observed. 11 However, the influence of dietary antioxidant intake was not evaluated in these previous studies.
These studies suggest that 8-oxo-dG levels may be a useful marker of free radical production from the disease or the treatment of the disease. This has not been previously investigated in children undergoing chemotherapy. In addition, 8-oxo-dG levels have not been evaluated in bone marrow samples of patients with leukemia, the site of origin of leukemia. Levels of modified DNA bases and antioxidant enzymes were measured in one small study of 9 children with ALL. 22 Elevated levels of 8-oxo-dG in the lymphocyte DNA were detected by GC/MS prior to initiation of therapy in cases compared to controls. Nine modified DNA bases, including 5-hydroxycytosine and 8hydroxyadenine, were identified in this study, and 7 were elevated when compared to controls. Levels of 3 antioxidant enzymes (superoxide dismutase, catalase, and glutathione peroxidase) were also lower in the lymphocytes of patients with ALL as compared to controls.
Children undergoing treatment for ALL receive multiagent chemotherapy, many agents of which are associated with free radical production, especially cytosine arabinoside 23 and methotrexate. 24 We report the results of an observational study of newly diagnosed children with ALL investigating blood mononuclear cell 8-oxo-dG levels plus a pilot study investigating the levels of 8-oxo-dG in bone marrow of children undergoing treatment for ALL. We hypothesized that (1) 8-oxo-dG levels will serve as a marker of the leukemic burden and therefore the levels of 8-oxo-dG will decrease with attainment of remission, (2) 8oxo-dG levels will serve as a marker of DNA damage from chemotherapy, (3) higher 8-oxo-dG levels will be associated with an increase in chemotherapy-related side effects, and (4) dietary intake of antioxidants will be inversely correlated with levels of 8-oxo-dG.
Materials and Methods

Recruitment
Children between the ages of 1 and 21 years, with newly diagnosed ALL, were recruited for the study ( Table 1 ). The study was open to children who were being treated on the Children's Cancer Group standard or high-risk protocols ( Table 2 ). Informed consent was obtained per the standards of the Institutional Review Boards of New York Presbyterian Hospital and other participating institutions.
Study Procedures
The study was a prospective observational study of antioxidant status in 103 children and adolescents with ALL undergoing treatment. Blood (14 mL) was collected at 3 regularly scheduled visits. Data on fasting status was collected for each subject. The first sample collection occurred before any chemotherapy was given (diagnosis), the second at the end of 28 days of interim maintenance therapy (3 months from diagnosis), and the third at the end of 28 days of delayed intensification therapy, an aggressive chemotherapy regimen (6 months from diagnosis). Fasting bone marrow (3-5 mL) was collected in a small pilot sample (n = 16) of individuals at 2 regularly scheduled visits. The first sample collection occurred before any chemotherapy was given (day 0) and the second at the end of 28 days of induction chemotherapy (day 28). The chemotherapy agents and dosages administered during this time period are listed in Table 1. A 24-hour food recall and a food frequency questionnaire (FFQ) 25 were administered on the same days as the blood collection for the majority of subjects. A nutritionist at each of the sites conducted the 24-hour food recall on day 0, day 28 of induction, day 28 of interim maintenance (IM), and day 28 of delayed intensification (DI). Interviewers followed a script to probe for intake. The 95 Youth/Adolescent Food Frequency Questionnaire (Channing Laboratory, Harvard Medical School) was used to assess intake over the previous 3 months plus use of a vitamin supplement. For the majority, the parent or guardian completed the FFQ.
Bone Marrow and Blood Collection
Blood and bone marrow were collected into heparin tubes and were protected from light. Samples were shipped to the Herbert Irving Comprehensive Cancer Center Biomarker Core Facility at Columbia University for processing within 24 hours after collection. Blood and bone marrow were kept under subdued light until isolation of mononuclear cells by centrifugation over Histopaque 1077 (Sigma Chemical Co., St. Louis, Mo).
Laboratory Analysis
After collection of all samples, the 3 samples from the same individual were batched for analysis with the laboratory blinded to batching and time point.
Plasma Vitamins C and E, Total Carotenoids, and Lipids
Total Ascorbate Analysis Total ascorbic acid was determined by HPLC analysis of deproteinized plasma in which complete reduction of the dehydroascorbic acid was accomplished by addition of homocysteine according to Behrens and others. 26 Samples were injected onto a Bio-Sil ODS 5S 150 × 4 mm reverse-phase column (Bio-Rad, Richmond, Calif) and analyzed by HPLC (Millennium System, Waters Associates, Milford, Mass) using an amperometric electrochemical detector (model LC4B, Bioanalytical Systems, West Lafayette, Ind). A total of 10 µg/mL of ascorbic acid was used as a standard.
Vitamin A and E Analysis
Retinol and α-tocopherol concentrations in plasma were determined simultaneously by HPLC according to the procedure of Bieri and others. 27 Plasma samples were deproteinized, extracted in hexane, dried down, and then reconstituted in an ethanol/methanol solution. This sample was injected onto a J′ SPHERE ODS reverse-phase column, (YMC, Willington, NC) and analyzed by HPLC (Millennium System, Waters Associates, Milford, Mass) using a multiwave length detector, (model 490, Waters Associates, Milford, Mass). Concentrations of retinol and α-tocopherol standards (Sigma, St. Louis, Mo) were measured on a spectrophotometer (model DU640, Beckman Instruments, Fullerton, Calif) with an extinction coefficient of 1835 (1%, 1 cm) for retinol and 71 (1%, 1 cm) for αtocopherol.
Total Carotenoids
Carotenoids in plasma were extracted into hexane and measured by a colorimetric procedure according to Roels et al 28 on a spectrophotometer (model DU640, Beckman Instruments, Fullerton, Calif) with an absorbance of 452 nm, using an extinction coefficient of 2550 (1%, 1 cm).
HDL/LDL Cholesterol and Triglycerides
The Lipid and Lipo-protein Laboratory of the Division of Preventative Medicine and Nutrition at Columbia University analyzed cholesterol and triglycerides. Total cholesterol and triglyceride concentrations were analyzed by standardized enzymatic methods (Boehringer Mannheim, Germany) using a Hitachi 704 automated spectrophotometer (Toyko, Japan). HDL cholesterol concentrations were analyzed in the same manner after precipitation of apoB-containing lipoproteins with phosphotungstic acid, 29 with use of reagents supplied by Boehringer Mannheim (St. Louis, Mo). LDL cholesterol levels were calculated using the Friedewald formula. 30 Total lipid was determined from the sum of total cholesterol and triglyceride.
Oxidative Damage in Blood and Bone Marrow Mononuclear Cells by Immunofluorescence
Smear slides were made immediately after isolation of mononuclear cells, air dried, then fixed for 3 minutes in cold methanol followed by dipping in cold acetone. Slides were stored at 80°C until stained. 8-oxo-dG was detected in mononuclear and bone marrow cells us-ing monoclonal antibody IF7, 31 as described previously. 10 Briefly, slides were treated with RNase A (100 µg/mL) at 37°C for 1 hour and with proteinase K (10 µg/mL) at room temperature for 10 minutes. Then the DNA was denatured by treatment with 4 N HCl for 10 minutes at room temperature. Samples were neutralized with 50 mM Tris base for 5 minutes and nonspecific binding blocked with 10% normal goat serum. Primary antibody 1F7 (1:1 dilution of hybridoma supernatant) was incubated on slides overnight in a cold room (5°C). Bound antibody was detected with fluorescein isothiocyanate-labeled secondary antiserum (ICN Pharmaceuticals, Costa Mesa, Calif).
Slides were counterstained with propidium iodide (1 µg/mL). Nuclear fluorescence staining was quantitated using a Nikon Eclipse E600 microscope (Melville, NY) attached to a Hamamatsu ORCA100 cooled digital camera (Bridgewater, NJ). Ten randomly selected fields were located, and 5 cells in each field were counted using Image-Pro software (Media Cybernetics, Silver Spring, Md).
As a quality control, a lymphoblastoid cell line was pretreatment of the antibody with 8-oxo-dG (1 µg/mL for 30 minutes at room temperature).
Side Effects and Disease Status
Data on adverse effects of chemotherapy were abstracted from the patient medical chart on day 28 of induction, day 28 of IM, and day 28 of DI. The data collected for each of the 3 time points included number of days of hospitalization, chemotherapy dose reductions for hematologic and nonhematologic toxicity, delay in scheduled therapy, use of total parenteral nutrition or oral nutrition support, incidence of infection, and other grade 3 or 4 hematologic and nonhematologic toxicity as defined by the National Cancer Institute Common Toxicity Criteria, version 2. In addition, the requirement for a major change in the treatment protocol for progressive disease, relapse, or severe toxicity (termed off study) was recorded for each time point. The relationship between intake of nutrients at time 0 and disease status was investigated. Rapidity of response to therapy was evaluated following the first 7 days (high-risk patients) or 14 days (standard-risk patients) of therapy. Remission status was ascertained at the end of 28 days of treatment. The percentage of lymphoblasts present in a 100 cell count of the bone marrow was calculated. If less than 5% of the 7-day (high-risk patients) or 14-day (standard-risk patients) bone marrow was lymphoblasts, then the bone marrow was classified as a rapid early responder. A bone marrow with 5% to 25% lymphoblasts was classified as an intermediate responder, and a bone marrow with greater than 25% lymphoblasts was classified as a slow early responder. Remission was attained if less than 5% of the bone marrow cells were lymphoblasts and recovery of normal hematopoiesis was detected on a bone marrow sample obtained on day 28 of induction therapy.
Nutrient Intake Analysis
The 24-hour recall was used for the pilot data only. Nutrient calculations for the 24 
Statistical Analysis
The primary end point for this study was comparison of day 0 to day 28 interim maintenance versus day 28 delayed intensification levels of 8-oxo-dG (measured as relative staining intensity) in mononuclear cells from the blood. A pilot study investigated changes in bone marrow after 28 days of treatment.
Changes in 8-oxo-dG levels in mononuclear cells from the blood over time were investigated with repeated measures analysis of variance. The distribution of blood mononuclear cell 8-oxo-dG concentrations was highly skewed; therefore, we used logtransformed data. The potential confounders age, gender, race, and fasting status were included in the models. Because of the small sample size, the difference between levels of 8-oxo-dG in the bone marrow was investigated using the Wilcoxon signed rank test.
To explore the relationship between 8-oxo-dG and plasma antioxidants plus vitamin A and the risk of side effects, quality-of-life score, and disease status, we employed regression analysis adjusting for other factors: age, gender, race, z score, and fasting status. Because the distributions of vitamins A, C, and E and total carotenoid were highly skewed, we analyzed nutrient plasma concentration using square root transformed values for all but total carotenoids, where log-transformed data were used.
The relationship between the level of 8-oxo-dG and intake of vitamins A, C, E, β-carotene, and total carotenoids was investigated using the linear regression method. Analysis was performed on both total intake (T) for vitamins A, C, E, and carotenoids and dietary intake (D) alone, adjusted for supplement use for vitamins A, C, and E. Formal analyses used linear regression, incorporating age, race, gender, fasting status, z score, and energy as possible cofounders. Fasting status was defined as no nourishment in the preceding 8 hours either by mouth, tube, or intravenously.
Because the distribution of antioxidant intake (vitamins A, E, total carotenoid, and β-carotene) was highly skewed, we analyzed intake using the square root transformed values as this transformation created a normal distribution. The Wilcoxon signed rank test was used to analyze changes in antioxidant intake from day 0 to day 28 for the pilot study. The degree of correlation of response to chemotherapy and 8-oxo-dG bone marrow levels was analyzed using the Pearson correlation coefficient. All statistics were calculated using the SPSS version 10.0 software package.
Results
The study population consisted of 103 newly diagnosed patients with ALL. Forty-two percent were female, and 58% were male. The majority were white (66%); 14% were African American, 13% Hispanic, and 4% Asian. The median age was 6.7 years (range, 1-18 years). Data were available for 71 subjects at all 3 time points. Sixty-six percent were on a standard-risk protocol, and 34% were on a high-risk protocol. Sixtyfive percent of the subjects were defined as rapid early responders to chemotherapy, 22% as intermediate responders, and 13% as slow early responders.
Blood 8-oxo-dG Levels
The distribution of 8-oxo-dG levels, expressed as relative staining intensity, decreased between diagnosis and IM (P = .01) and increased between IM and DI to its original level (P = .005; Figure 1 ). The mean level in the blood was 216 ± 96 at diagnosis, 173 ± 110 on day 28 IM, and 220 ± 101 on day 28 DI. There was no difference in 8-oxo-dG from samples collected locally versus those that were shipped to the laboratory overnight. Representative nuclear staining of lymphocytes for 8oxo-dG is illustrated in Figure 2 . Control slides stained with nonspecific antibody, stained with specific antibody after treatment of cells with DNase, or stained with specific antibody preabsorbed with antigen before use showed low background levels of staining (data not shown).
Relationship of 8-oxo-dG and Plasma Antioxidant Concentrations
Relationships between 8-oxo-dG and plasma vitamins A, C, E/total lipid and total carotenoids were analyzed using regression analysis adjusting for age, gender, race, z score, and fasting status. There was no relationship between blood 8-oxo-dG at diagnosis and any of the plasma antioxidants listed above.
At IM, patients with higher 8-oxo-dG had a lower plasma vitamin C concentration (P = .018, B = -0.272, R 2 = 0.143), lower plasma total carotenoids (P = .012, B = -0.301, R 2 = 0.174), and higher vitamin E/total lipid (P = .004, B = 0.332, R 2 = 0.177). At DI, patients with higher 8-oxo-dG had higher vitamin E/total lipid (P = .010, B = 0.292, R 2 = 0.156) and higher vitamin E (P = .020, B = 0.265, R 2 = 0.152). At IM, fasting was associated with a lower 8-oxo-dG level (P = .043, B = -0.237, R 2 = 0.064), and at DI, fasting was associated with a higher 8-oxo-dG level (P = .022, B = 0.266, R 2 = 0.071). Total lipid in the plasma increased between diagnosis and DI (P < .01).
Relationship of 8-oxo-dG and Antioxidant Intake
The relationship between 8-oxo-dG and intake, both total and dietary, of vitamins A, C, and E; β-carotene; and total carotenoids was analyzed using regression analysis adjusting for age, gender, race, z score, and energy intake. The only associations observed were at IM. Higher 8-oxo-dG levels were associated with lower β-carotene consumption (P = .037, B = -0.274, R 2 = 0.093), and at DI, higher 8-oxo-dG levels were associ-ated with lower dietary vitamin A consumption (P = .003, B = -0.440, R 2 = 0.176). The use of a vitamin/ mineral, herbal, or antioxidant supplement had no influence on 8-oxo-dG levels. 
Relationship of 8-oxo-dG and Chemotherapy Regimen Toxicity and Disease Status
Bone Marrow Pilot Data
Bone marrow samples were obtained from 16 patients at diagnosis and from 10 patients at the end of induction chemotherapy. The distribution of bone marrow 8-oxo-dG levels, expressed as relative staining intensity, at diagnosis and the end of induction chemotherapy remained stable over time, with no significant difference between the 2 time points. The mean value for relative staining intensity for 8-oxo-dG in the bone marrow was 180 ± 73 (range, 80-315) at day 0 and 175 ± 140 (range, 52-500) at day 28. Data on response to chemotherapy were available for the 16 patients in the pilot study. Twelve of the 16 patients were classified as rapid early responders, 2 were classified as intermediate responders, and 2 were slow early responders. No correlations were observed between rapid or slow response to chemotherapy and the levels of 8-oxo-dG in the bone marrow for either time point.
The only predictive variable for 8-oxo-dG levels in the bone marrow was the intake of vitamin E at diagnosis (P = .03, B = 0. 245; Table 3 ). Vitamin C and βcarotene intake had no predictive value on 8-oxo-dG levels for either time point in bone marrow.
Discussion
A monoclonal antibody-based immunohistochemical method was used to monitor levels of 8-oxo-dG in blood and bone marrow mononuclear cells of children undergoing treatment for ALL. Our study demonstrated that with initiation of therapy, there is a reduction in the level of 8-oxo-dG and with aggressive chemotherapy, 8-oxo-dG levels increase. It is possible that the decrease in free radical production associated with a reduction in leukemic cell burden with attainment of remission not only was large enough to mask the effect of free radical production from chemotherapy during the first less-intensive IM phase but also led to an overall reduction in 8-oxo-dG levels. Comparison with a control group of healthy children (study in progress) will determine if the level of 8-oxo-dG may have initially been elevated at diagnosis as a consequence of leukemic cell infiltration disease. It is likely that the increase in 8-oxo-dG levels associated with the DI phase reflected more specifically the effects of the chemotherapy. Since the majority of patients in this study were rapid early responders to chemotherapy, no relationship could be seen with response to chemotherapy and 8-oxo-dG levels in blood or bone marrow mononuclear cells.
This observational pilot study is the first to study a marker of oxidative damage directly in the bone marrow of children with acute lymphoblastic leukemia and to study this marker at diagnosis and after the initiation of chemotherapy. Even though no significant changes in the level of 8-oxo-dG with initiation of therapy were observed in bone marrow cells, the absence of a significant change may be a result of the limitation of the small sample size.
A different internal oxidant environment in the plasma of children being treated for ALL at IM versus DI was noted. Increasing plasma vitamin C and total carotenoid concentrations were related to a lower 8oxo-dG level as expected but only at IM. Perhaps the free radical load was so large at DI that plasma antioxidants had no appreciable effect on protecting DNA. In contrast, increased plasma vitamin E/total lipid levels were associated with an increase in blood 8-oxo-dG during both IM and DI.
The diet had a very limited effect on 8-oxo-dG during IM and DI with no effect observed at diagnosis. Since increases in dietary β-carotene and vitamin A were found to relate to a decrease in 8-oxo-dG, dietary counseling, especially advice on increasing fruit and vegetable intake once treatment has begun, could be of significance in affecting 8-oxo-dG levels. In contrast, supplement intake had no effect on 8-oxo-dG levels in this study. This observation is in agreement with prior observations in which carrot juice but not a β-carotene supplement was associated with a reduction in the levels of 8-oxo-dG. 20 This suggests that the total pool of isoflavones and carotenoids, not just βcarotene, is responsible for the antioxidant effect seen in fruits and vegetables on 8-oxo-dG.
Results from this study supported our hypothesis that a higher level of 8-oxo-dG would be related to an increase in side effects observed. It is not clear why a relationship was found only at IM and not at DI when therapy was more intense and the level of 8-oxo-dG was higher.
In the previous study of children with ALL, higher levels of 8-oxo-dG in lymphocyte DNA at diagnosis were detected, compared to disease-free children. 22 There were substantial intraindividual variations among patients in the levels of the oxidized DNA bases, whereas the controls had less variation. This wide variability in levels of 8-oxo-dG was also observed in our study. We are currently conducting a study to measure 8-oxo-dG in blood from healthy siblings of subjects in this study. Comparison with healthy children would provide information specifically on the effects of the leukemia. Study of additional markers of DNA oxidative damage may provide a more comprehensive assessment of oxidative damage. In the previous study of children with ALL, 7 of the 9 DNA-modified bases assayed were elevated including 5-hydroxycytosine, 5-hydroxy-5methylhydantoin, and 5-hydroxyhydantoin. 22 Another study demonstrated that the DNA modified base, 5hydroxymethyluracil, was elevated after doxorubicin chemotherapy in a group of adult patients with a variety of cancer types. 15 Future studies of oxidative damage should include a comprehensive panel of DNA base damage.
8-oxo-dG in Children During Leukemia Treatment
Our study demonstrates that oxidative DNA damage decreases after the start of chemotherapy and increases with aggressive chemotherapy. Since 8-oxo-dG can be routinely measured using immunohistochemical methods in blood and bone marrow cells of children with leukemia, follow-up studies should evaluate children with leukemia over a longer time period to investigate the duration of the elevation in 8-oxo-dG levels and the effect of the diet at these later time points.
